A comparative randomized double-blind clinical trial of pivampicillin and ampicillin in lower respiratory tract infections.
The efficacy and safety of pivampicillin was compared with that of ampicillin in 52 patients suffering from lower respiratory tract infections. Equimolar doses of pivampicillin (350 mg) and ampicillin (250 mg) were administered three times daily for 15 days in identical code-labeled capsules. Each patient received only one drug in a random double-blind order. Clinical as well as objective assessment showed that pivampicillin was comparatively more effective and safer than ampicillin on both the 7th and 15th day of treatment. The reduction in the volume and purulence of sputum and in cough and dyspnea was more marked with pivampicillin. The overall success rate was higher and the side effects were fewer with pivampicillin.
D000667:Ampicillin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D001831:Body Temperature; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D010366:Peak Expiratory Flow Rate; D010917:Pivampicillin / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000503:physiopathology
D010917:Pivampicillin; D000667:Ampicillin